RNA interference technology is emerging as a very potent tool to obtain a cellular knockdown of a desired gene. In this work we used vector-based RNA interference to inhibit vascular endothelial growth factor (VEGF) expression in prostate cancer in vitro and in vivo. We demonstrated that transduction with a plasmid carrying a small interfering RNA targeting all isoforms of VEGF, dramatically impairs the expression of this growth factor in the human prostate cancer cell line PC3. As a consequence, PC3 cells loose their ability to induce one of the fundamental steps of angiogenesis, namely the formation of a tube-like network in vitro. Most importantly, our ''therapeutic'' vector is able to impair tumor growth rate and vascularization in vivo. We show that a single injection of naked plasmid in developing neoplastic mass significantly decreases microvessel density in an androgen-refractory prostate xenograft and is able to sustain a long-term slowing down of tumor growth. In conclusion, our results confirm the basic role of VEGF in the angiogenic development of prostate carcinoma, and suggest that the use of our vector-based RNA interference approach to inhibit angiogenesis could be an effective tool in view of future gene therapy applications for prostate cancer. Cancer Gene Therapy (2005) 12, 926-934.
P
rostate cancer is the most common solid tumor and the second leading cause of cancer mortality among men in the United States and European countries. 1, 2 Conventional therapies, either local or systemic, are often not beneficial and have a significant negative impact on quality of life because they induce several side effects (incontinence, impotence, loss of libido and other). Thus, there is a great interest in identifying alternative approaches that improve efficacy and reduce side effects. 3 Antiangiogenic therapies might be a new option for treatment of advanced prostatic carcinoma. 4 Several data suggest that growth and metastasis of prostate cancer are highly dependent on angiogenesis, 5 the process of formation of new blood vessels that facilitates delivery of nutrients and oxygen and removal of catabolites. In turn, tumor cells themselves promote neoangiogenesis by releasing growth factors, which sustain endothelial cell survival, migration and proliferation. One of the principal angiogenesis-inducing factors is vascular endothelial growth factor-A (VEGF-A); VEGF-A induces endothelial cell proliferation, differentiation and migration, thus being important for blood vessels formation. 6 VEGF is present at significant levels in neoplastic but not in benign hyperplasic or normal prostate cells in vivo. 7, 8 Moreover, it has been observed that plasma levels of VEGF are increased in patients with metastatic prostate cancer compared to patients with localized tumors. 9 Huss et al 10 have described a ''progression-switch'' model to explain the molecular changes observed in clinical and TRAMP (transgenic adenocarcinoma of the mouse prostate) prostate cancer progression, which depend on the specific actions of the various components of the ''VEGF axis'', and have demonstrated that these molecules could indeed represent specific therapeutic targets for prostate carcinoma (PCa).
In this study we have used RNA interference to inhibit VEGF production in human PCa cells. RNA interference (RNAi) is the process of sequence-specific, post-transcriptional gene silencing, mediated by small interfering RNAs (siRNAs), which are homologous to the silenced gene. 11 The ability of RNAi to efficiently suppress target genes has provided not only a rapid means for assessing the effects of the loss of gene function but also a new promising therapeutic tool against cancer. [12] [13] [14] Recently, the efficacy of synthetic siRNAs in slowing tumor growth was demonstrated for PCa. 15 We performed a vector-based RNA interference strategy as a tool against prostate cancer cells, by designing a short hairpin RNA (shRNA) driven by the U6 RNA polymerase III promoter and targeting specifically all VEGF isoforms expressed in prostate cancer cells. We show that anti-VEGF shRNA is able to suppress VEGF secretion in the human PCa cell line PC3, resulting in an inhibition of in vitro angiogenesis. Most importantly, in an in vivo experiment in SCID mice, the direct intratumoral injection of the plasmid encoding the anti-VEGF shRNA dramatically suppressed growth of a hormone-refractory human prostate xenograft tumor, demonstrating that the anti-VEGF shRNA expressing plasmid exhibits in vivo anticancer efficacy, which is associated with antiangiogenic activity.
Materials and methods

Cell lines and tissue culture conditions
The human PCa cell line PC3 was a kind gift of Dr Costanzo Moretti. Cells were maintained in RPMI-1640 medium supplemented with 5% heat-inactivated foetal bovine serum, 20 mM L-glutamine, 100 U/ml of penicillin G sodium, 100 mg/ml of streptomycin sulphate. Human umbilical vein endothelial cells (HUVEC single donor, Cambrex Bio Science S.r.l., Milano) were maintained in RPMI-1640 medium supplemented with 15% heat-inactivated foetal bovine serum, 1 mg/ml heparin, 45 mg/ml endothelial cell growth supplement (ECGS), 10 mM Sodium pyruvate, 20 mM L-glutamine, 1% MEM essential amino acids without L-glutamine, 0.5% MEM nonessential amino acids, 100U/ml of penicillin G sodium, 100 mg/ml of streptomycin sulphate, 0.25 mg/ml Fungizone. To allow cellular adhesion, HUVEC were grown in T75 flasks treated overnight with gelatin type B 2% solution, from bovine skin. All cells were maintained in a humidified atmosphere containing 5% CO 2 at 371C.
All media and serum were purchased from Gibco BRLLife Science Technologies, Inc., Gaithersburg, MD, except heparin and gelatin (Sigma, Italy) and ECGS (BD Biosciences, Bedford, MA, USA).
Vectors construction
To construct shRNAs targeting human VEGF or rat VEGF, the following oligonucleotides were designed. For human shRNA 18fw: 5 0 -tcgacTGGGTGCATTGGAGC CTTGttcgCAAGGCTCCAATGCACCCATTTTt-3 0 and 18rev 5 0 -ctagaAAAATGGGTGCATTGGAGCCTTGcg aaCAAGGCTCCAATGCACCCAg-3 0 ; for rat shRNA 92fw 5 0 -tcgagCAGAAGGGGAGCAGAAAGCttcgGCT TTCTGCTCCCCTTCTGTTTTt-3 0 and 92rev 5 0 -ctagaA AAACAGAAGGGGAGCAGAAAGCcgaaGCTTTCT GCTCCCCTTCTGg-3 0 . Oligonucleotides contain a 19-nucleotide sequence in sense and antisense orientation separated by a 4-nucleotide spacer (lower case underlined letters) and overhangs (lower case italic letters) specific for the SalI and XbaI restriction sites at the 5 0 -and 3 0 -end respectively. 18fw and 18rev or 92fw and 92rev were mixed in equimolar amount (500 pmol each), heated for 10 minutes at 891C, then gradually cooled to 651C in annealing buffer (Tris-HCl 50 mM, MgCl 2 10 mM, DTT 10 mM, ATP 1 mM, BSA 25 mg/ml, DMSO 10%). Double strands obtained were cloned into cohesive ends of the SalI/XbaI linearized plasmid vector pAVU6 þ 27. 16 Recombinant chimerical plasmids were checked by restriction enzyme analysis and sequencing, and correct constructs were named pAVU6-18 (for siRNA targeting human VEGF) and pAVU6-92 (for siRNA targeting rat VEGF).
The VAI5 plasmid, carrying the sequence of an anti-VEGF ribozyme, was constructed as previously described. 17 Transient transfection of PC3 cell line and collection of conditioned media Transient cotransfection was carried out using 900 ng of chimeric constructs (pAVU6-18, pAVU6-92, pAVU6 þ 27, VAI5 or VAI-BglII) and 100 ng of pEGFP-C3 (Clontech) with 2 ml Lipofectamine 2000 (Gibco BRL-Life Science Technologies) in 24-well plates with 5 Â 10 4 PC3/well, as recommended by the manufacturer. At 48 hours after transfection, cells were analyzed by fluorescence microscopy to calculate the transfection efficiency. For each well, cell number in four random microscopic fields was counted and transfection efficiency for each sample was estimated as the mean value of green fluorescent protein (GFP) expressing cells over 100 cells per field. Conditioned media were collected and subjected to a short centrifugation (10 minutes 1000 rpm) to eliminate cellular debris.
ELISA measurement of secreted VEGF
To quantitate the secreted VEGF in conditioned media of transfected cells, human VEGF ELISA was performed using human VEGF Duo Set ELISA kit (R & D Systems) following the manufacturer's protocol. Assays were repeated at least twice. Results of the ELISA assay were expressed as pg VEGF/ml/10 4 cells, normalized for the transfection efficiency.
In vitro endothelial cell tube formation assay
The assay was performed as in Ciafre`et al. 17 Briefly, 0.5 ml of Matrigel (10 mg/ml, Collaborative Research, Bedford, MA) were dispensed into 13 mm/diameter tissue culture wells and allowed to polymerize for 1 hour at 371C. 5 Â 10 5 HUVE cells were plated for each well, followed by the addition of conditioned media obtained from pAVU6-18-transfected PC3 cells, or from empty vector-transfected cells. The RPMI-1640 medium, supplemented with 10% serum and 20 mM L-glutamine, was employed as the negative control, whereas human recombinant vascular endothelial growth factor VEGF 165 (20 ng/ml, R & D System, Oxon, UK) was the positive control. Plates were incubated at 371C and the development of tube-like structures was monitored for 24 hours.
In vivo tumor xenograft model PC3 cells were trypsinized, washed twice with PBS, collected and resuspended in PBS; the viability of collected cells was tested by staining with trypan blue. To establish PC3 tumor xenografts in mice, 6-week-old B-17 SCID mice were injected subcutaneously in the right flank with 1.6 Â 10 6 PC3 cells in 200 ml of PBS. When tumor volume reached 80.7758.8 mm 3 , mice were randomized for therapy in two experimental groups.
For DNA therapy, animals were anesthetized with metadomine 1 mg/kg and ketamine 75 mg/kg, and 50 mg of pAVU6-18 or pAVU6 þ 27 in 20 ml of sterile physiological solution (NaCl 0.9%) were directly injected into tumor mass. Tumor volume was determined weekly by external measurements with a caliper and calculated as
, where L and l represent the larger and the smaller tumor diameter. The observations were ended for ethical reasons after 3 weeks from the day of DNA injection, when in the control group the tumor volume became large compared with animal size. At this time, animals were killed and tumors were immediately frozen in dry ice or fixed in formalin.
Animal care was provided according to the institutional guidelines: the European Directive 86/609/EEC (''The Council Directive on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes''), which was ratified in Italy by Legislative Decree 116/92.
Immunohistochemical staining for CD31 expression
Formalin-fixed paraffin-embedded tumors were treated for immunohistochemical staining for CD31. Tumor sections (5 mm thick) were collected on positively-charged ''polysine'' slides (International PBI, Milano, Italy), deparaffinized, rehydrated and endogenous peroxidases were quenched. Antigen retrieval was performed with proteinase K (Sigma-Aldrich) diluted in Tris-HCl 0.2 M pH 7.2, at 371C for 30 minutes. Slides were then incubated overnight at 41C with a rat monoclonal primary antibody specific for CD31 (PharMingen) at a 1:200 dilution in 1% rabbit serum in PBS. All slides were subsequently incubated with a 1:200 dilution of biotin-conjugated rabbit anti-rat secondary antibody (Vector Laboratories) for 30 minutes at room temperature. Immunoreactive species were detected with the ABC staining system according to the manufacturer's recommendations (Santa Cruz Biotechnologies). Sections were counterstained with hematoxylin.
Quantitative analysis of microvessel density in tumors treated with empty vector or pAVU6-18 was performed by counting CD-31 positive structures per microscopic field; for each sample four microscopic fields ( Â 20) in three different sections were counted.
Statistical analysis
Statistical analysis was performed using Mann-Whithey U test for the analysis of variants (Jandel Scientific).
Results
Construction of a plasmid expressing the anti-human VEGF shRNA
We have recently observed that four different VEGF isoforms are commonly expressed in the human prostate cancer cell line PC3, namely VEGF 189, 165, 148 and 121 (unpublished data). Therefore, in order to efficiently inhibit VEGF secretion from this cell line, it was necessary to generate an interfering RNA able to guide the degradation of all these isoforms. The specific role of each of the VEGF isoforms is not yet completely understood, but it is hypothesized that they may perform different functions in the various steps of angiogenesis during tumor progression and metastasis. [18] [19] [20] For these reasons, we performed a bioinformatic analysis and selected sequences that would be conserved in all isoforms and also good candidates as targets for RNAi. The data presented in this paper were obtained with the one sequence that gave us the best results. This sequence is located 18 nucleotides downstream of the ATG codon (Fig 1a) , it is not predicted to fold into any secondary structure and it is a favourable target for anti-VEGF shRNA. A corresponding DNA sequence acting as a template was inserted into the eukaryotic expression vector pAVU6 þ 27, where U6 RNA-polymerase III promoter drives the synthesis of RNA, along with a stretch of thymidines and a polymerase III stem terminator to function as the transcription termination signal. The transcript is expected to fold back to form a shRNA composed by two aligned 19-nucleotide regions in an inverted orientation separated by a 4-nucleotide loop (Fig 1b) . In the cell, shRNA is further cleaved by Dicer, 21 to generate a siRNA targeting all VEGF mRNA isoforms at the above indicated site. This plasmid construct was named pAVU6-18 and the derived siRNA is siRNA18. To investigate the specificity against human VEGF mRNA of the RNA interference process induced by our siRNA, we also cloned in the same vector a sequence that produces a siRNA directed against rat VEGF mRNA in a region with poor homology with human VEGF (from nucleotide 93 to nucleotide 111 of rat VEGF 164, GenBank Accession # M32167). This plasmid, pAVU6-92, produces siRNA92 and was used as a negative control.
In summary, in order to obtain a stable suppression of gene expression, we cloned our shRNA-18 into a eukaryotic expression vector under the control of the ubiquitously expressed PolIII U6 promoter. The resulting plasmid has the advantage of being effectively introduced into different cells and has been successfully used to drive the expression of hairpin RNA. 14, 22, 23 Thus, shRNA-18, after being processed into siRNA, should be able to trigger a stable and efficient suppression of the corresponding VEGF mRNA.
RNAi
Transfection of PC3 with pAVU6-18 strongly inhibits VEGF secretion
As a first approach to evaluate the effect of siRNA18 on VEGF expression, we performed a transient transfection in PC3 cells. Cells were transfected with empty vector or pAVU6-18 and pEGFP-C3, carrying the GFP cDNA to calculate the transfection efficiency (see Methods). At 48 hours after transfection, conditioned media were collected to perform an ELISA assay. Cell viability, as measured by trypan blue staining, was good (D90%) and comparable for all samples (data not shown). As shown in Figure 2a , VEGF expression in supernatants derived from pAVU6-18-transfected cells was almost undetectable, whereas in the control transfections we observed normal levels of VEGF, as compared with nontransfected PC3 cells (B110 pg/ml/10 4 cells). This is a good indication that the shRNA we have designed is able to impair VEGF secretion up to 100% when transiently expressed in carcinoma cell line PC3. Conversely, transfection with pAVU6-92, carrying a siRNA directed against a messenger different but highly related to our real target, did not have any effect on VEGF production from PC3, whereas we had previously demonstrated that it is effective against its correct target in C6 rat glioblastoma cells (data not shown). Thus, we show that the pAVU6-encoded siRNA-18 is acting via a specific anti-human VEGF interference, and not via a general gene expression, off-target downregulation. In parallel, we transfected PC3 cells with an anti-VEGF ribozyme previously described by our group and proven to be efficient in reducing VEGF secretion in a human glioblastoma cell line. 17 Indeed, this ribozyme was able to diminish VEGF production also in the PC3 prostate cancer model; however, it lowered the secreted amount of VEGF by less than 30%, a minor extent as compared to siRNA-18 (Fig 2a) . These results clearly show that the siRNA technology, compared with the ribozyme approach, is a more potent tool to inhibit gene expression and that siRNA18 is a specific means to strongly impair VEGF expression in a human prostate cancer cell line.
Conditioned medium of pAVU6-18-transfected cells has a poor angiogenic potential in vitro
To verify if the strong reduction of VEGF expression induced by siRNA18 had a consequence on PC3 angiogenic potential, we performed an angiogenic assay in vitro. In this assay HUVE cells seeded on Matrigel in the presence of appropriate growth factors (i.e. VEGF 20 ng/ml) are induced to proliferate, differentiate, branch and form tube-like structures (Fig 2b) . We tested conditioned media from transiently transfected PC3 cells to correlate the low VEGF level with an impaired ability to stimulate endothelial cells towards angiogenesis. As shown in Figure 2e , when HUVE cells were grown in the presence of conditioned medium from pAVU6-18-transfected PC3 cells, they failed to form any differentiated structure. It is evident that HUVE cells maintained an undifferentiated morphology, without any sign of sprouting, similarly to the negative control, represented by HUVE cells grown in the presence of nonconditioned medium (Fig 2c) . As expected, conditioned medium collected from empty vector-transfected cells did not affect the capability of HUVE cells to create a tube-like network on Matrigel (Fig 2d) . This in vitro morphological assay demonstrates that siRNA18 transduction greatly impairs the angiogenic potential of the PC3 PCa cell line, by inhibiting differentiation and sprouting of endothelial cells and thus a fundamental step of angiogenesis.
In vivo injection with pAVU6-18 slows the growth rate of prostate xenograft tumor
The in vitro data presented above suggest that pAVU6-18 inhibits angiogenesis and, if PC3 tumor growth in vivo is dependent on neovascularization, then expression of siRNA18 should also induce tumor growth inhibition. To assess the in vivo anticancer efficacy and therapeutic potential of pAVU6-18, we chose a PC3 tumor xenograft as a model of androgen refractory PCa, which is at present not curable with the classical therapies.
We subcutaneously inoculated 1.6 Â 10 6 PC3 cells in SCID mice; after injection, tumors were allowed to grow for 4 weeks until volume reached 80.7758.8 mm 3 , when RNAi to impair angiogenesis in prostate cancer F Wannenes et al neoplastic mass was barely palpable. Then mice were randomized and divided in two experimental groups: one group (n ¼ 8) received direct injection of ''therapeutic'' plasmid pAVU6-18 into the tumor mass, whereas the other (n ¼ 7) was injected with empty vector pAVU6 þ 27. As shown in Figure 3 , at the time point of killing, tumors in the control group had a volume of 553.5790.1 mm 3 , which was 6.8-fold larger than the starting volume, whereas pAVU6-18 injected tumors had a volume of 324.9764.8 mm 3 , resulting in a volume increment of only four-fold. Tumor growth delay was statistically significant (Po.0001) from day 14 after the beginning of therapy until the day the mice were killed.
During the second week after treatment (from point 2 to point 3 in the x-axis of the graph in Fig 3) we observed the strongest effect of pAVU6-18; in this period, the growth rate of controls was 54.4714.9 mm 3 /day whereas in the treated group it was 14.9711.1 mm 3 /day (Po.0001), demonstrating that the growth rate of control tumors was nearly four-fold greater compared with the treated ones. These preliminary data clearly show that a single injection of pAVU6-18 is able to slow down the growth of PC3-derived xenografts and, most importantly, it has a lasting effect on tumor development, being effective for at least 21 days. We decided to end the observations at this time for ethical reasons, as the tumor burden in control animals had begun impairing their motility and resulted in evident suffering.
Tumors treated with pAVU6-18 have a reduced microvessel density
Tumors were examined at necropsy, and marked differences were observed both by morphological analysis, and by specific immunohistochemical staining.
Upon macroscopical analysis, we observed evident morphological differences between control and treated samples. Figures 4a and b show that empty-vector injected tumors were larger than pAVU6-18 injected ones, as expected from the results of tumor growth rate. Most importantly, control tumors appeared very vascularized, and in several samples an angioma was present in the middle of the tumor mass, demonstrating that during the development of the neoplastic mass a remarkable angiogenic process had taken place. On the contrary, treated tumors were almost white and did not show any important vascular structure. These notable macroscopical differences represent our first in vivo indication that siRNA18 is able to impair tumor growth rate by inhibiting angiogenesis.
Next, to analyze at a molecular level, the connection between local intratumoral delivery of pAVU6-18 and tumor-associated neovascularization, we performed an immunohistochemical analysis on tumor sections by Figure 3 Growth rate of xenograft tumors. Each point represents the mean volume7standard deviation (n ¼ 7 for pAVU6 þ 27 and n ¼ 9 for pAVU6-18 injected mice). On the x-axis, point 1 represents the day of DNA injection; point 4 is the time of mice killing. **Po.0001. 
Discussion
The production of high levels of VEGF by solid tumors is a sign of poor prognosis with respect to disease progression as well as survival. 24 For PCa as for many others, VEGF is considered the preminent inducer of tumor vascularization. 25 Consequently, a tumor therapy targeting VEGF would be particularly efficacious in the treatment of PCa, as demonstrated by previous work where the inhibition of VEGF production was shown to reduce tumor growth in several experimental models. 26, 27 In this study we describe the efficacy of a single intratumoral injection of naked plasmid DNA encoding for an anti-VEGF siRNA to block VEGF expression in a human prostate cancer model both in vitro and in vivo. Recently, the ability of RNAi to efficiently and specifically suppress target genes has provided a new promising therapeutic tool against cancer. [12] [13] [14] SiRNAs have been used against several cancer targets, either as synthetic RNA oligonucleotides, 12, 28, 29 or as RNAi to impair angiogenesis in prostate cancer F Wannenes et al plasmid-encoded shRNAs, 30, 31 which are expected to be efficiently transcribed and subsequently processed to yield the mature, active form of siRNAs. Among the plasmid vectors that have been described for the expression of shRNAs, the great majority contains PolIII promoters, such as H1 or U6 promoters, which are ubiquitously expressed and in general very efficient in transcribing short RNA molecules, as they are primed to do in their natural context. 32, 33 In our plasmid, the anti-VEGF shRNA was placed under the control of the U6 promoter, and the expected transcribed molecule also retains the first 27 nucleotides of the U6 RNA. This feature has been proposed to be a stabilizing factor for the shRNA before it is processed to form the active siRNA. 16 Indeed, we show that the transfection of human prostate cancer cells with our pAVU6-18 plasmid results in a strong reduction of VEGF production, while its target specificity is demonstrated by the use of another, nonspecific shRNA, that has no effect on VEGF secretion. The functional consequence of the decrease in VEGF secretion is evident in vitro, where we measured the angiogenic potential of pAVU6-18 transfected cells using an endothelial cell differentiation assay; the transfected cells are no longer able to induce endothelial cells to form a tube-like network, as the major proangiogenic factor, VEGF, is reduced to very low concentrations.
The most remarkable results obtained using pAVU6-18, however, are those we achieved by the in vivo intratumoral injection of this plasmid in PC3 xenografts in SCID mice. Tumor growth is delayed in treated animals and microvascular density, measured as CD-31 positive cells, is significantly lower than in control tumors, providing a proof of the true antiangiogenic activity of pAVU6-18. Although we cannot exclude a possible direct effect of siRNA-18 on PC3 proliferation, we think that this is a very remote hypothesis, possibly contributing to only a very little part of the general antitumor effect in vivo. Indeed, our data show that VEGF does not have any strong autocrine effect on PC3 proliferation rate in vitro, even though these cells express VEGFR2. 34 For example, exogenous administration of different amounts of VEGF165 (from 0.1 to 100 ng/ml) to cultured PC3 cells does not affect their proliferation rate, whereas an antisense-mediated 50% inhibition of VEGF secretion does not result in any increase in PC3 apoptotic rate in several clones analyzed (data not shown).
Also, it would be interesting to investigate if the pAVU618-induced reduction of microvessel density results into increased hypoxia, which in turn could lead to enhanced expression of other angiogenic factors. This might explain the slight increase in growth rate observed between the third and the fourth week as compared to second and third week.
Recently, Takei et al 15 published a study on the use of chemically synthesized anti-VEGF siRNA in the PC3 experimental model. Their approach is based on repeated (6 Â ) injections of atelocollagen-complexed RNA oligonucleotides into PC3 s.c. xenografts, which resulted in a potent decrease of tumor angiogenesis and growth. The improvement in the approach presented in our present work lays in the use of a vector-based RNAi as a therapeutic tool, as plasmid-mediated transduction is predicted to ensure a stable expression of the shRNAs, virtually as long as transduced tumor cells persist. We think that this feature can explain how a single injection of pAVU6-18 has an inhibitory effect on tumor growth, which other groups could obtain only by multiple treatments. 14, 15, 35 In addition, in view of future therapeutic applications, it is not of secondary importance that such a plasmid-mediated approach is by far cheaper than the use of chemically synthesized siRNAs, which require a costly process of production.
In conclusion, we believe that our anti-VEGF siRNA18 represents, in its present state, a powerful tool to target PCa vascularization and growth. The most widely used vectors for the in vivo transduction of prostate tumors to date are adenoviral vectors, which can also be engineered to harbor prostate-specific promoters driving the expression of ''therapeutic'' genes. 36, 37 As an alternative approach, lentiviral vectors are now considered an efficacious means for the stable transduction of PCa cells in vivo, as they can infect cells with a low mitotic index (such as PCa cells), and apparently do not have any important collateral effects. 38, 39 Thus, we propose that cloning shRNA18 into an adenoviral or a lentiviral vector could make it an effective gene therapy agent for prostate cancer, which is, in general, a very suitable disease to be treated via gene therapy, due to the easy accessibility of the host organ and to the common long preclinical latency period, which make preventive gene therapy strategies feasible. 40 Moreover, based on the observation that the greater the degree of vascularization in a solid tumor, the lower the likelihood of responsiveness to conventional anticancer therapies, 41 siRNA18 treatment, which clearly diminishes intratumoral vessel density, might represent a valid adjuvant for classical therapies. A number of data have been collected to show that the combination of more than one anticancer approach is the best way to proceed to stop tumor progression. As tumor cells are particularly able to switch on new angiogenic pathways to escape the inhibition of one angiogenic factor, the construction of a bicistronic vector encoding our anti-VEGF siRNA18 coupled to another siRNA targeting a different angiogenic factor might enhance the antitumor effect of our approach. In particular, antiangiogenic treatment is cytostatic rather than cytotoxic, and can block tumor growth but cannot induce regression of disease, and it has been shown that the employment of more than one antiangiogenic agent is more effective than single-agent therapies. 42 A ''direct'' angiogenesis inhibitor, such as a soluble factor, could be flanked by an ''indirect'' one, such as our anti-VEGF siRNA, in order to affect a broad spectrum of angiogenic pathways. In addition, by combining antiangiogenic therapy with more conventional therapies, such as chemotherapy, radiation therapy or immunotherapy, the limitations of each method should be overcome, and the effects of the different approaches summed up. 43, 44 RNAi to impair angiogenesis in prostate cancer F Wannenes et al
